[1] M. Kehrer, S. Koob, A. Strauss, D.C. Wirtz, J. Schmolders, [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy], Z. Orthop. Unfall. 155(5) (2017) 575-586.
[2] C. Gerecke, S. Fuhrmann, S. Strifler, M. Schmidt-Hieber, H. Einsele, S. Knop, The Diagnosis and Treatment of Multiple Myeloma, Dtsch Arztebl Int 113(27-28) (2016) 470-6.
[3] H. Zhang, X. Huang, L. Ye, G. Guo, X. Li, C. Chen, L. Sun, B. Li, N. Chen, X. Xue, B Cell-Related Circulating MicroRNAs With the Potential Value of Biomarkers in the Differential Diagnosis, and Distinguishment Between the Disease Activity and Lupus Nephritis for Systemic Lupus Erythematosus, Front. Immunol. 9 (2018) 1473.
[4] C. Papadaki, M. Stratigos, G. Markakis, M. Spiliotaki, G. Mastrostamatis, C. Nikolaou, D. Mavroudis, S. Agelaki, Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer, Breast Cancer Res. 20(1) (2018) 72.
[5] A. Tölle, C.C. Blobel, K. Jung, Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017, Biomark. Med. 12(6) (2018) 667-676.
[6] A. Allegra, A. Alonci, S. Campo, G. Penna, A. Petrungaro, D. Gerace, C. Musolino, Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review), Int. J. Oncol. 41(6) (2012) 1897-912.
[7] B. Dewdney, A. Trollope, J. Moxon, D. Thomas Manapurathe, E. Biros, J. Golledge, Circulating MicroRNAs as Biomarkers for Acute Ischemic Stroke: A Systematic Review, J. Stroke Cerebrovasc. Dis. 27(3) (2018) 522-530.
[8] P.S. Mitchell, R.K. Parkin, E.M. Kroh, B.R. Fritz, S.K. Wyman, E.L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K.C. O'Briant, A. Allen, D.W. Lin, N. Urban, C.W. Drescher, B.S. Knudsen, D.L. Stirewalt, R. Gentleman, R.L. Vessella, P.S. Nelson, D.B. Martin, M. Tewari, Circulating microRNAs as stable blood-based markers for cancer detection, Proc. Natl. Acad. Sci. U. S. A. 105(30) (2008) 10513-8.
[9] Q. Li, L. Liu, W. Li, Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis, Tumour Biol. 35(10) (2014) 10467-78.
[10] X. Qu, M. Zhao, S. Wu, W. Yu, J. Xu, J. Xu, J. Li, L. Chen, Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma, Med. Oncol. 31(10) (2014) 219.
[11] L. Kubiczkova, F. Kryukov, O. Slaby, E. Dementyeva, J. Jarkovsky, J. Nekvindova, L. Radova, H. Greslikova, P. Kuglik, E. Vetesnikova, L. Pour, Z. Adam, S. Sevcikova, R. Hajek, Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance, Haematologica 99(3) (2014) 511-8.
[12] S.H. Jung, S.E. Lee, M. Lee, S.H. Kim, S.H. Yim, T.W. Kim, C.K. Min, Y.J. Chung, Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma, Haematologica 102(11) (2017) e456-e459.
[13] L. Besse, L. Sedlarikova, F. Kryukov, J. Nekvindova, L. Radova, O. Slaby, P. Kuglik, M. Almasi, M. Penka, M. Krejci, Z. Adam, L. Pour, S. Sevcikova, R. Hajek, Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma, PLoS One 10(9) (2015) e0137294.
[14] C.I. Jones, M.V. Zabolotskaya, A.J. King, H.J. Stewart, G.A. Horne, T.J. Chevassut, S.F. Newbury, Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma, Br. J. Cancer 107(12) (2012) 1987-96.
[15] J. Chi, E. Ballabio, X.H. Chen, R. Kušec, S. Taylor, D. Hay, D. Tramonti, N.J. Saunders, T. Littlewood, F. Pezzella, J. Boultwood, J.S. Wainscoat, C.S. Hatton, C.H. Lawrie, MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival, Biol. Direct 6 (2011) 23.
[16] W. Wang, M. Corrigan-Cummins, E.A. Barber, L.M. Saleh, A. Zingone, A. Ghafoor, R. Costello, Y. Zhang, R.J. Kurlander, N. Korde, A.M. Roccaro, I.M. Ghobrial, O. Landgren, K.R. Calvo, Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression, J. Mol. Diagn. 17(6) (2015) 669-78.
[17] I.P.N. Bong, C.C. Ng, P. Baharuddin, Z. Zakaria, MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy, Genes Genomics 39(5) (2017) 533-540.
[18] Y. Li, X. Deng, X. Zeng, X. Peng, The Role of Mir-148a in Cancer, J. Cancer 7(10) (2016) 1233-41.
[19] X. Liu, J. Li, F. Qin, S. Dai, miR-152 as a tumor suppressor microRNA: Target recognition and regulation in cancer, Oncol. Lett. 11(6) (2016) 3911-3916.
[20] J. Yuan, Z. Su, W. Gu, X. Shen, Q. Zhao, L. Shi, C. Jin, X. Wang, H. Cong, S. Ju, MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN, Cancer Biomark. 24(3) (2019) 279-289.
[21] S. Kumar, S.K. Sharawat, A. Ali, V. Gaur, P.S. Malik, S. Kumar, A. Mohan, R. Guleria, Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients, Curr. Probl. Cancer 44(4) (2020) 100540.
[22] W. Zhang, Y. Li, miR-148a downregulates the expression of transforming growth factor-β2 and SMAD2 in gastric cancer, Int. J. Oncol. 48(5) (2016) 1877-85.
[23] M.S. Han, J.M. Lee, S.N. Kim, J.H. Kim, H.S. Kim, Human Papillomavirus 16 Oncoproteins Downregulate the Expression of miR-148a-3p, miR-190a-5p, and miR-199b-5p in Cervical Cancer, Biomed Res Int 2018 (2018) 1942867.
[24] H. Zhang, Y. Wang, T. Xu, C. Li, J. Wu, Q. He, G. Wang, C. Ding, K. Liu, H. Tang, F. Ji, Increased expression of microRNA-148a in osteosarcoma promotes cancer cell growth by targeting PTEN, Oncol. Lett. 12(5) (2016) 3208-3214.
[25] T. Lang, Y. Nie, MiR-148a participates in the growth of RPMI8226 multiple myeloma cells by regulating CDKN1B, Biomed. Pharmacother. 84 (2016) 1967-1971.
[26] I.A. Paunescu, R. Bardan, A. Marcu, D. Nitusca, A. Dema, S. Negru, O. Balacescu, L. Balacescu, A. Cumpanas, I.O. Sirbu, B. Petrut, E. Seclaman, C. Marian, Biomarker Potential of Plasma MicroRNA-150-5p in Prostate Cancer, Medicina (Kaunas) 55(9) (2019).
[27] S.A. Dybos, A. Flatberg, J. Halgunset, T. Viset, T. Rolfseng, S. Kvam, H. Skogseth, Increased levels of serum miR-148a-3p are associated with prostate cancer, APMIS 126(9) (2018) 722-731.
[28] G.E. Grieco, D. Cataldo, E. Ceccarelli, L. Nigi, G. Catalano, N. Brusco, F. Mancarella, G. Ventriglia, C. Fondelli, E. Guarino, I. Crisci, G. Sebastiani, F. Dotta, Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism, Noncoding RNA 4(4) (2018).
[29] X. Peng, J. Wang, C. Zhang, K. Liu, L. Zhao, X. Chen, G. Huang, Y. Lai, A three-miRNA panel in serum as a noninvasive biomarker for colorectal cancer detection, Int. J. Biol. Markers 35(3) (2020) 74-82.
[30] B. Li, Z. Xie, B. Li, miR-152 functions as a tumor suppressor in colorectal cancer by targeting PIK3R3, Tumour Biol. 37(8) (2016) 10075-84.
[31] F. Wang, H. Ying, B. He, Y. Pan, H. Sun, S. Wang, Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma, Tumour Biol. 37(4) (2016) 4945-53.
[32] H. Zhang, Y. Lu, S. Wang, X. Sheng, S. Zhang, MicroRNA-152 Acts as a Tumor Suppressor MicroRNA by Inhibiting Krüppel-Like Factor 5 in Human Cervical Cancer, Oncol. Res. 27(3) (2019) 335-340.
[33] H. Chen, H. Liu, H. Zou, R. Chen, Y. Dou, S. Sheng, S. Dai, J. Ai, J. Melson, R.A. Kittles, M. Pirooznia, M.J. Liptay, J.A. Borgia, Y. Deng, Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers, J. Cancer 7(5) (2016) 490-9.
[34] F. Matin, V. Jeet, L. Moya, L.A. Selth, S. Chambers, J.A. Clements, J. Batra, A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer, Sci. Rep. 8(1) (2018) 6653.
[35] P. Zarecki, M. Hackl, J. Grillari, M. Debono, R. Eastell, Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures, Bone 130 (2020) 115105.
[36] X. Jiang, L. Du, L. Wang, J. Li, Y. Liu, G. Zheng, A. Qu, X. Zhang, H. Pan, Y. Yang, C. Wang, Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer, Int. J. Cancer 136(4) (2015) 854-62.
[37] L. Wang, Y. Wang, J. Lin, MiR-152-3p promotes the development of chronic myeloid leukemia by inhibiting p27, Eur. Rev. Med. Pharmacol. Sci. 22(24) (2018) 8789-8796.
[38] M. Roux, C. Perret, E. Feigerlova, B. Mohand Oumoussa, P.J. Saulnier, C. Proust, D.A. Trégouët, S. Hadjadj, Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes, Nephrol. Dial. Transplant. 33(12) (2018) 2201-2207.
[39] X. Tong, X. Wang, C. Wang, L. Li, Elevated levels of serum MiR-152 and miR-24 in uterine sarcoma: potential for inducing autophagy via SIRT1 and deacetylated LC3, Br. J. Biomed. Sci. 75(1) (2018) 7-12.